Background: Inflammation is implicated in many aging-related disorders. In animal models, menopause leads to increased gut permeability and inflammation. Our primary objective was to determine if gut permeability increases during the menopause transition (MT) in women. Our exploratory objectives were to examine whether greater gut permeability is associated with more inflammation and lower bone mineral density (BMD).Methods: We included 65 women from the Study of Women's Health Across the Nation. Key measures were markers of gut permeability (gut barrier dysfunction [fatty acid binding protein 2 [FABP2]) and immune activation secondary to gut microbial translocation (lipopolysaccharide binding protein [LBP], soluble CD14 [sCD14]); inflammation (highsensitivity CRP); and lumbar spine (LS) or total hip (TH) BMD. Results: In our primary analysis, FABP2, LBP, and sCD14 increased by 22.8% (P = 0.001), 3.7% (P = 0.05), and 8.9% (P = 0.0002), respectively from pre-to postmenopause. In exploratory, repeated measures, mixed-effects linear regression (adjusted for age at the premenopausal visit, body mass index, race/ethnicity, and study site), greater gut permeability was associated with greater inflammation, and lower LS and TH BMD. Conclusions: Gut permeability increases during the MT. Greater gut permeability is associated with […]
(U01NR004061, U01AG012505, U01AG012535, U01AG012531, U01AG012539, 48 U01AG012546, U01AG012553, U01AG012554, U01AG012495). 49
INTRODUCTION 50
Inflammation contributes to the pathogenesis of numerous medical disorders that commonly 51 affect older adults, including osteoporosis, diabetes mellitus, cardiovascular disease, and 52 dementia (1-10); this is often referred to as "inflammaging" (3, 11). Beyond chronological aging, 53 the postmenopausal state may independently contribute to greater inflammation in older women. 54
In animal models, chemical or surgical menopause leads to down-regulation of epithelial 55 junction proteins, gut barrier dysfunction and increased gut permeability (12). This, in turn, 56 permits the translocation of microbes from the intestinal lumen into the subepithelial space, 57 triggering immune cells to produce pro-inflammatory cytokines (12). Whether an increase in gut 58 permeability accompanies the menopause transition (MT) in humans is uncertain. If gut 59 permeability does increase, whether it is associated with inflammation and end organ 60 manifestations is also unknown. 61
62
The overarching goals of this pilot study were to determine if gut permeability increases during 63 the MT, and if such an increase were confirmed, to explore whether gut permeability is 64 associated with inflammation and bone mineral density (BMD). In this report, subsequent use of 65 the term "gut permeability" refers to its indirect assessment using these blood markers. We used 66 bone as a model end-organ system because increased gut permeability mediates inflammation 67 and hypogonadal BMD loss in rodents, and probiotics that reduce gut permeability (12) or 68 inflammation (13-15) can decrease bone resorption (12-15) and prevent bone loss (12, 15). Our 69 primary hypothesis was that gut permeability increases from pre-to postmenopause. Our 70 exploratory hypothesis was that greater gut permeability is associated with greater inflammation 71 (assessed by high-sensitivity CRP [hs-CRP]) and lower BMD (assessed by dual-energy X-ray 72 absorptiometry [DXA]). 73
74
The parent study for this pilot was the Study of Women's Health Across the Nation (SWAN), a 75 multi-racial/ethnic, longitudinal cohort study of the MT. We obtained two stored plasma samples 76 for each study participant from the SWAN Repository: one from premenopause (operationalized 77 as 3-5 years before the final menstrual period [FMP]), and one from postmenopause 78 (operationalized as 3-5 years after the FMP). To assess gut permeability, we assayed indirect 79 markers of gut barrier dysfunction (fatty acid binding protein 2 [FABP2]) and immune activation 80 secondary to gut microbial translocation (lipopolysaccharide binding protein [LBP] , soluble 81 CD14 [sCD14]). FABP2 is considered a marker of gut epithelial cellular dysfunction because it 82 is expressed by enterocytes, and released into the circulation when gut epithelial cells are 83 damaged (16, 17) . LBP and sCD14 are deemed markers of immune activation secondary to gut 84 microbial translocation because they are produced by hepatocytes and monocytes/macrophages, 85 respectively, in response to lipopolysaccharide (a product of gram negative bacterial, of which 86 the gut is the predominant source) (18, 19) . 87
RESULTS 88

Participant Characteristics in Pre-to Postmenopause 89
We included a total of 65 women. At the premenopausal visit, subjects were, on average, 49.9 90 years of age, and 3.8 years before their FMP. At the postmenopausal visit, mean age was 57.7 91 years and mean time after the FMP was 4.0 years (Table 1) . 92
93
Results for Primary Objective: Change in Gut Permeability during the Menopause Transition 94
From pre-to postmenopause, median E2 decreased from 51.7 to 15.5 pg/ml (p<0.0001, 95
Wilcoxon signed-rank test), and FSH increased from 14.8 to 84.3 mIU/ml (p<0.0001, Wilcoxon 96 signed-rank test) (Table 1 ). E2 and FSH had skewed distributions, so were log-transformed for 97
analyses. During the same period, FABP2, LBP, and sCD14 increased from 1,298 to 1,595 98 pg/ml, 5892 to 6,112 ng/ml, and 948 to 1,032 ng/ml, respectively. 99
100
In our primary analysis, we used the paired t-test at a two-sided alpha of 0.05 to determine if the 101 rise in each gut permeability marker was statistically significant. Using this approach, the 102 increases in FABP2 (p=0.001), LBP (p=0.05), and sCD14 (p=0.0002) were considered 103 statistically significant. We further examined the associations of these markers with E2 and FSH 104 (log transformed), using repeated measures, mixed effects linear regression (Table 2) . Adjusted 105 for chronological age at the premenopausal visit, race/ethnicity, BMI, and study site, lower E2 106 and greater FSH (tested separately) were associated with greater FABP2 and sCD14. Each 50% 107 decrement in E2 was associated with 77 pg/ml greater FABP2 (p=0.02), and 28 ng/ml greater 108 sCD14 (p=0.001). Analogously, each two-fold increment in FSH was associated with 113 pg/ml 109 greater FABP2 (p=0.001), and 34 ng/ml greater sCD14 (p<0.0001). Neither E2 nor FSH was 110 significantly associated with LBP. 111 112
Results for Exploratory Objective: Associations of Gut Permeability with Inflammation and 113
Bone Mineral Density 114
Median hs-CRP increased from 1.4 mg in premenopause to 1.6 mg/L in postmenopause, but this 115 increase did not reach statistical significance (p=0.06, Wilcoxon signed-rank test). The 116 distribution of hs-CRP was skewed. During the same period, mean LS and TH BMD decreased 117 from 1.104 to 0.986 and from 0.964 to 0.901 g/cm 2 , respectively (p<0.00001 for both sites). 118
Scatter plots of FABP2, LBP, and sCD14 vs. hs-CRP are presented in Figure 1 . Figure 2 contains 119 scatter plots of FABP2, LBP, sCD14 and hs-CRP vs. BMD; we present plots for LS only, as 120 those for FN were similar (data not shown). 121
122
To test whether greater FABP2, LBP, or sCD14 is associated with greater hs-CRP, we used 123 repeated measures, mixed effects linear regression (Table 3) . hs-CRP was log transformed for 124 these analyses because of skewed distributions. Adjusted for age at the premenopausal visit, 125 race/ethnicity, BMI, and study site, each SD increment in LBP and sCD14 was associated with 126 2.32-(p<0.001) and 1.44-(p=0.001) fold greater hs-CRP, respectively. FABP2 was not 127 associated with hs-CRP. 128
129
To examine the associations of FABP2, LBP, sCD14 and hs-CRP with BMD, we again used 130 repeated measures, mixed effects linear regression. Adjusted for the same covariates listed 131 above, each SD increment in FABP2 was associated with 0.021 and 0.017 g/cm 2 lower LS 132 (p=0.05) and TH BMD (p=0.02), respectively. Similarly, each SD increment in sCD14 was 133 associated with 0.051 lower LS BMD (p=0.0001) and 0.025 g/cm 2 lower TH BMD (p=0.004). 134 LBP was not associated with BMD. In contrast, each two-fold increment in hs-CRP was 135 associated with 0.024 g/cm2 lower LS (p<0.0001) BMD; hs-CRP was not associated with TH 136 BMD. 137
DISCUSSION 138
The primary objective of this longitudinal, pilot study was to determine if gut permeability 139 (assessed non-invasively using markers of gut barrier dysfunction [FABP2] and immune 140 activation secondary to microbial translocation [LBP, sCD14]) increases during the MT. Upon 141 observing this increase, our exploratory objective was to examine whether greater gut 142 permeability was associated with greater inflammation and lower BMD. Our primary analysis 143 supports the hypothesis that, in humans, gut permeability increases from pre-to postmenopause. 144
Exploratory analyses suggest that greater gut permeability (LBP and sCD14) is associated with 145 greater inflammation (hs-CRP), and both greater gut permeability and inflammation (FABP2, 146 sCD14, hs-CRP) are associated with lower BMD. 147
148 Several prior studies have reported the effects of aging, but not the MT, on gut permeability in 149 humans. One cross-sectional analysis found that gut permeability was higher in older vs. younger 150 men and women (20). Subsequently, the longitudinal Cardiovascular Health Study determined 151 that sCD14 increased by 0.4% per year in men and women over 65 years (p<0.0001) (21). This is 152 the first human study, to our knowledge, to demonstrate that gut permeability (assessed 153 indirectly) increases during the MT. This finding is additionally supported by data that lower E2 154 and greater FSH are associated with greater FABP2 and sCD14. 155
156
In rodent models, increased gut permeability underlies an MT-related increase in inflammation. 157
Chemical or surgical menopause leads to decreased expression of epithelial junction proteins 158 (e.g., claudins 1, 2, 3, and Jam3), and increased gut permeability (12). This, in turn, permits the 159 translocation of microbes from the intestinal lumen into the subepithelial space, triggering 160 immune cells to produce pro-inflammatory cytokines (12). Our exploratory analyses suggest that 161 immune activation from gut microbial translocation (LBP and sCD14) is associated with greater 162 inflammation (hs-CRP). The implications are that a mechanism that contributes to inflammation 163 in rodents may similarly be present in humans, and that MT-related changes in gut physiology 164 warrants further research as a potential therapeutic target for preventing inflammation. 165
166
The physiologic importance of increased gut permeability and inflammation is highlighted in 167 rodent studies in which probiotics that reduce gut permeability (12) or inflammation (13-15) can 168 decrease bone resorption (12-15) and prevent bone loss (12, 15). In humans, a prior SWAN study 169 reported that greater inflammation (assessed by hs-CRP) is associated with lower BMD (cross-170 sectional), lower hip strength (cross-sectional), and more future fractures (4). We also have 171 ongoing analyses using the full SWAN Bone Cohort to examine the associations of change in hs-172 CRP and IL-6 with change in BMD. Here, we report that greater FABP2 and sCD14 are 173 associated with lower LS and TH BMD, and greater hs-CRP is associated with lower LS BMD. 174
While these findings suggest a link between gut permeability, inflammation and BMD, this study 175 was not sufficiently powered to explicitly relate changes in FABP2, LBP, sCD14, and hs-CRP to 176 concurrent change in BMD. We also could not discern whether inflammation vs. circulating 177 bacterial products contribute more to lower BMD. 178 179 Gut permeability can be assessed by various methods. Histologic and electron microscopic 180 evaluation of biopsy samples provides direct information on gut barrier integrity and mucosal 181 tight junctions (22). Alternatively, enteral administration of non-digestible markers affords a 182 functional assessment of gut permeability (22-24). However, neither methodology is well-suited 183 to community-based cohort designs. For this pilot study, we indirectly assessed gut permeability 184 using markers of gut barrier dysfunction (FABP2) and immune activation secondary to gut 185 microbial translocation (LBP, sCD14). These markers are associated with adverse outcomes in 186 pathologic conditions characterized by increased gut permeability (e.g., liver cirrhosis, 187 inflammatory bowel disease, HIV, and sepsis) (18, 25-28). That FABP2, LBP, and sCD14 188 increase from pre-to postmenopause suggests that they are sensitive and precise enough to in exploratory analyses, we related these gut permeability markers to a marker of inflammation 204 and BMD. This study is a critical first step in elucidating whether a mechanism that contributes 205 to inflammation and disease in animal models is similarly present in humans. 206
207
The principal limitation of this study is the modest sample size of 65 women, which was, 208 nonetheless, powered to our primary objective: to determine if gut permeability increases during 209 the MT. Our primary analysis upheld that all tested markers of gut permeability increase from 210 pre-to postmenopause. While our exploratory analyses suggest a link between gut permeability, 211 inflammation and BMD, not all predictor-outcome associations were significant. In addition, this 212 study was not sufficiently powered to explicitly examine the longitudinal associations between 
Marker of Gut Permeability 271
To assess gut permeability, we measured markers of gut barrier dysfunction (FABP2) and 272 immune activation secondary to microbial translocation (LBP, sCD14) using citrated plasma 273 samples that were accessed from the SWAN Repository. FABP2 was measured using the 274 Quantikine Human FABP2/I-FABP ELISA (R&D Systems). The lower limit of detection (LLD) 275 for this assay is 6.21 pg/mL. The intra-assay coefficient of variation (CV) was <4.1%. LBP and 276 sCD14 were assayed in multiplex, using the Luminex platform with custom-made panels (R&D 277 Systems). This platform uses microparticles that are pre-coated with analyte-specific antibodies 278 and incubated with diluted plasma samples, followed by a biotin antibody, and lastly by a 279 streptavidin-phycoreythin conjugate. The fluorescence intensity of each analyte's microparticles 280 are then quantified using a Bioplex 200 (Luminex) System Analyzer, and the data analyzed using 281
Bioplex Manager software. The LLD for the LBP is 0.0839 ng/ml, and the intra-assay CV was 282 <2.9%. The LLD for sCD14 is 0.0366 ng/ml, and the intra-assay CV was <2.9%. 283
284
Markers of Ovarian Function 285
To examine whether reduced ovarian function is associated with greater gut permeability across 286 the MT, we used previously measured E2 and FSH. Serum E2 was measured in duplicate with a 287 modified, off-line ACS:180 (E2-6) immunoassay using an ACS:180 automated analyzer (Bayer 288 Diagnostics Corp., Tarrytown, New York). The average between duplicates was recorded in the 289 dataset and used in analyses. The LLD was 1.0 pg/ml, and the intra-assay CV was 6.4%. Serum 290 FSH was measured in singlicate with a 2-site chemiluminometric assay (Bayer Diagnostics  291 Corp., Tarrytown, New York). The LLD was 1.05 mIU/ml, and intra-assay CV was 6.0%. For 292 this pilot, we only included women whose premenopausal E2 and FSH measurements were 293 obtained in the EFP of a spontaneous menstrual cycle. 294 295
Marker of Inflammation: High-sensitivity C-reactive Protein (hs-CRP) 296
To assess whether the associations of gut permeability with inflammation, and of inflammation 297 with BMD, we used hs-CRP. CRP was measured at SWAN baseline, and at follow-up visits 1, 3-298 7, 9, 10, 12, and 15. Owing to the long duration of follow up, the laboratories that measured CRP 299 and the assays employed changed with time. SWAN used 3 CRP assays and a fourth, hs-CRP 300 assay as the calibration standard to harmonize all assays. The fourth assay was also used to 301 obtain results for analytes that had been below the LLD on each of the 3 original assays. From 302 baseline to follow-up visit 7, CRP was measured by Medical Research Laboratories. CRP assays 303 for samples collected at follow-up visit 9 and later were conducted by the CLASS Laboratory at 304 the University of Michigan (Ann Arbor, MI) using the Alfa Wassermann ACE analyzer. Assays 305 and their calibration are described below. 306 307 CRP assay 1: From baseline to follow-up visit 7, CRP was measured using an ultrasensitive rate 308 immunonephelo-metric method, with a LLD of 0.3 mg/L (BN100; Dade-Behring, Marburg, 309
Germany). The intra-assay CV at CRP concentrations of 0.5 and 22.0 mg/L were 10-12% and 5-310 7%, respectively. CRP assay 2: For follow-up visit 12, CRP was assayed using the ACE 311
UltraWide Range assay, a latex-enhanced turbidimetric in vitro immunoassay (Alfa 312
Wassermann, West Caldwell, NJ). The LLD was 0.1 mg/L, and the intra-assay CV at CRP 313 concentrations of 0.5 mg/L and 9.8 mg/L were 5.7-7.0% and 1.2%, respectively. CRP Assay 3: 314
Samples from follow-up visit 9, 10 and 15 were assayed using a high sensitivity immunoassay 315 (Alfa Wassermann, West Caldwell, NJ). The LLD was 0.1 mg/L, and the intra-assay CV at CRP 316 concentrations of 0.5 and 9.8 mg/L were 5.7-7.0% and 1.2%, respectively. CRP assay 4: For 317 approximately 25% of all samples run between baseline and follow-up 15, CRP was below the 318 LLD of the original 3 assays outlined above. In these instances, an additional sample was 319 retrieved from the Repository and CRP was measured using the Human High Sensitivity CRP 320 ELISA (R&D Systems, DCRP00), a quantitative sandwich enzyme immunoassay. The lower 321 LLD for this assay was 0.10 pg/ml. The remaining 75% of results (those above the LLD for the 3 322 Los Angeles). To determine the short-term in vivo precision error, each study site measured LS 337 and TH BMD twice in 5 women with complete subject repositioning between duplicate scans. 338
Using the root mean square SD approach, the precision error in SWAN was 1.4% at the LS and 339 2.2% at the TH. An anthropomorphic spine phantom was circulated between sites for cross-site 340 calibration. Standard quality control phantom scans were conducted before each BMD 341 measurement session. If necessary, these were used to adjust for longitudinal machine drift. 342 343
Additional Measures and Variables 344
The following were included in analyses as covariates: age (years), race/ethnicity (Black, 345 Chinese, Japanese, White), and body mass index (BMI [weight in kilograms/(height in 346 meters) 2 ]), based on height and weight measured using standardized protocols and with 347 participants wearing light clothing and no shoes. To assess our primary hypothesis, we used the paired t-test at a 2-sided alpha of 0.05 to test the 366 mean within-person change in FABP2, LBP, and sCD14 from pre-to postmenopause against the 367 null hypothesis of zero change. We considered a p-value of 0.05 and lower to be statistically 368 significant. To additionally examine whether ovarian function is associated with gut 369 permeability, we used repeated measures, mixed effects linear regressions with E2 or FSH as 370 continuous primary predictors, and FABP2, LBP, or sCD14 as continuous outcome measures 371 (with each primary predictor-outcome pair modeled separately). Models included a random 372 intercept at the individual level to account for clustering. Covariates were chronologic age at the 373 premenopausal visit, BMI, race/ethnicity, and SWAN study site. 374
375
To test our secondary hypothesis, we used repeated measures, mixed effects linear regression 376 with FABP2, LBP, sCD14, or hs-CRP as continuous primary predictors, and hs-CRP or LS or 377 TH BMD as continuous outcomes variables. As above, each primary predictor-outcome pair was 378 modeled separately, and all models included a random intercept at the individual level. 379
Covariates were chronologic age at the premenopausal visit, BMI, race/ethnicity, and study site. 380 381 For all relational analyses stipulated above, we used mixed effects, repeated measures linear 382 regression because this approach is best suited for detecting predictor-outcome associations in 383 small samples. This is because this type of model accounts for the associations of both between-384 women and within-woman differences in the predictor with corresponding differences in the 385 outcome. 386 387
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corresponding to the plasma sample times; and 5) have not used sex steroid medications or bone 569 modifying agents in between their pre-and postmenopausal pilot study visits. A total of 621 570 women met these criteria. From this potential pool of subjects, the SWAN Repository randomly 571 selected 65 women for this pilot study. Associations assessed by repeated measured, mixed effect linear regression with FABP, 593 LBP, or sCD14 as continuous outcome variable, and E2 or FSH (log transformed) as 594 Table 3 598 Gut permeability assessed by FABP2 (barrier dysfucntion), LBP and sCD14 (immune 612 activation secondary to gut microbial translocation). 613
Associations of gut permeability a with a marker of inflammation
